Literature DB >> 9129865

Anthelmintics. A comparative review of their clinical pharmacology.

N de Silva1, H Guyatt, D Bundy.   

Abstract

Virtually all the important helminth infections in humans can be treated with one of 5 anthelmintics currently in use: albendazole, mebendazole, diethylcarbamazine, ivermectin and praziquantel. These drugs are vital not only for the treatment of individual infections, but also useful in controlling transmission of the more common infections. This article reviews briefly the pharmacology of these 5 drugs, and then discusses current issues in the use of anthelmintics in the treatment and/or control of soil-transmitted nematode infections, filariasis, onchocerciasis, schistosomiasis (and other trematode infections), neurocysticercosis and hydatidosis. Mebendazole and albendazole are most effective against intestinal nematodes, but are contraindicated during the first trimester of pregnancy. The efficacy of prolonged therapy with these 2 drugs for treatment of larval cestode infections has not yet been established. Diethylcarbamazine is widely used to treat and control lymphatic filariasis, but adverse effects related to death of microfilariae or damage to adult worms may be marked. While ivermectin has been used in the treatment of patients with onchocerciasis, it is also undergoing investigation against lymphatic filariae. Praziquantel, used to treat schistosome infections, is also effective in other trematode infections and adult cestode infections.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9129865     DOI: 10.2165/00003495-199753050-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  210 in total

1.  'Albendazole' in intestinal helminthiasis.

Authors:  A Ahmad; A Zohra; N Yasmin
Journal:  J Pak Med Assoc       Date:  1986-05       Impact factor: 0.781

2.  A clinical evaluation of the efficacy of mebendazole in the treatment of trichuriasis.

Authors:  R G Sargent; T D Dotterer; A M Savory; P R Lee
Journal:  South Med J       Date:  1975-01       Impact factor: 0.954

3.  Effect of semiannual treatments of ivermectin on the prevalence and intensity of Onchocerca volvulus skin infection, ocular lesions, and infectivity of Simulium ochraceum populations in southern Mexico.

Authors:  M A Rodriguez-Perez; M H Rodriguez; H M Margeli-Perez; A R Rivas-Alcala
Journal:  Am J Trop Med Hyg       Date:  1995-05       Impact factor: 2.345

4.  Clinical trial of mebendazole on whipworm and hookworm.

Authors:  D Bunnag; T Harinasuta; C Vasuvat; Y Visuthikosol; C Vidhyanont; N Chulajata
Journal:  J Med Assoc Thai       Date:  1978-06

5.  Association of the therapeutic activity of praziquantel with the reversal of Symmers' fibrosis induced by Schistosoma mansoni.

Authors:  M A Homeida; I el Tom; T Nash; J L Bennett
Journal:  Am J Trop Med Hyg       Date:  1991-09       Impact factor: 2.345

6.  Comparison of the therapeutic efficacy and side effects of a single dose of levo-praziquantel with mixed isomer praziquantel in 278 cases of schistosomiasis japonica.

Authors:  M H Wu; C C Wei; Z Y Xu; H C Yuan; W N Lian; Q J Yang; M Chen; Q W Jiang; C Z Wang; S J Zhang
Journal:  Am J Trop Med Hyg       Date:  1991-09       Impact factor: 2.345

7.  Weight gain of Kenyan school children infected with hookworm, Trichuris trichiura and Ascaris lumbricoides is improved following once- or twice-yearly treatment with albendazole.

Authors:  L S Stephenson; M C Latham; E J Adams; S N Kinoti; A Pertet
Journal:  J Nutr       Date:  1993-04       Impact factor: 4.798

8.  Five cases of encephalitis during treatment of loiasis with diethylcarbamazine.

Authors:  B Carme; J Boulesteix; H Boutes; M F Puruehnce
Journal:  Am J Trop Med Hyg       Date:  1991-06       Impact factor: 2.345

9.  Comparative efficacy of clearing-dose and single high-dose ivermectin and diethylcarbamazine against Wuchereria bancrofti microfilaremia.

Authors:  D G Addiss; M L Eberhard; P J Lammie; M B McNeeley; S H Lee; D F McNeeley; H C Spencer
Journal:  Am J Trop Med Hyg       Date:  1993-02       Impact factor: 2.345

10.  Albendazole in the treatment of onchocerciasis: double-blind clinical trial in Venezuela.

Authors:  B L Cline; J L Hernandez; F J Mather; R Bartholomew; S N De Maza; S Rodulfo; C A Welborn; M L Eberhard; J Convit
Journal:  Am J Trop Med Hyg       Date:  1992-10       Impact factor: 2.345

View more
  23 in total

Review 1.  Drug resistance in human helminths: current situation and lessons from livestock.

Authors:  S Geerts; B Gryseels
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

Review 2.  [Therapy of tropical diseases after returning from travel].

Authors:  G D Burchard; H Sudeck
Journal:  Internist (Berl)       Date:  2003-05       Impact factor: 0.743

3.  Intestinal nematode infection and anaemia in developing countries.

Authors:  Shally Awasthi; Donald Bundy
Journal:  BMJ       Date:  2007-05-26

Review 4.  Neurocysticercosis--New Millennium, ancient disease and unending debate.

Authors:  G Narula; K S Bawa
Journal:  Indian J Pediatr       Date:  2003-04       Impact factor: 1.967

5.  In vitro and in vivo effects of flubendazole on Echinococcus granulosus metacestodes.

Authors:  M Elissondo; L Ceballos; M Dopchiz; V Andresiuk; L Alvarez; S Sánchez Bruni; C Lanusse; G Denegri
Journal:  Parasitol Res       Date:  2006-12-15       Impact factor: 2.289

6.  Evaluation of the therapeutic and protective effects of ivermectin and permethrin in controlling of wound myiasis infestation in sheep.

Authors:  G S Al-Eissa; H A Gammaz; M F Mohamed Hassan; A M Abdel-Fattah; K M Al-Kholany; M Y Halami
Journal:  Parasitol Res       Date:  2008-05-06       Impact factor: 2.289

Review 7.  A review and meta-analysis of the impact of intestinal worms on child growth and nutrition.

Authors:  Andrew Hall; Gillian Hewitt; Veronica Tuffrey; Nilanthi de Silva
Journal:  Matern Child Nutr       Date:  2008-04       Impact factor: 3.092

8.  Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  J Clin Exp Oncol       Date:  2013

9.  Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Tubulin/Microtubule Inhibitors on the Cytotoxic Anti-Neoplastic Potency of Epirubicin-(C3-amide)-Anti-HER2/neu Synthesized Utilizing a UV-Photoactivated Anthracycline Intermediate.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  Cancer Clin Oncol       Date:  2012-11

10.  The costs and cost-effectiveness of mass treatment for intestinal nematode worm infections using different treatment thresholds.

Authors:  Andrew Hall; Sue Horton; Nilanthi de Silva
Journal:  PLoS Negl Trop Dis       Date:  2009-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.